Consistent with the presence of common disease mechanisms in patients with or without IL36RN mutations, classical psoriasis treatments, including granulocyte and monocyte adsorption apheresis (a procedure in which one or more blood components are removed to treat a disease) (158, 222), secukinumab (anti-IL-17A) (171, 217), anakinra (antagonist of IL-1R1) (145, 176), ustekinumab (anti-IL-12/IL-23) (175), or infliximab (anti-TNFα) (168) have been used successfully in patients carrying IL36RN variants. Here, IL37 is linked to psoriasis.